

Rare melanocortin-4 receptor pathway diseases: Clinical features and genetic confirmation

Rare melanocortin-4 receptor (MC4R) pathway diseases can be caused by genetic variants within the pathway, which impair signalling that controls hunger.¹

Hyperphagia (pathological, insatiable hunger) and early-onset, severe obesity are clinical features of a rare MC4R pathway disease.¹ If you see these features in your patients, they may be living with a rare MC4R pathway disease.¹



Also known as an abnormally strong sensation of hunger or desire to eat.

Characteristics and behaviours include:

	Heightened and
5	prolonged hunger

Longer time to reach satiety

Shorter duration of satiety

Severe preoccupation with food (hyperphagic drive)


Food-seeking behaviours (sneaking or stealing food)

Distress and functional impairment if denied food



Early-onset, severe obesity³

Defined as having a BMI ≥120% of the 95th percentile and onset before the age of 5.4



a) Patients with general obesity have a BMI >30 kg/m² by age 14 to 16 years and do not have a variant in LEP, LEPR, or MC4R.

Reprinted with permissions from Springer Nature from Kohlsdorf K, et al. Int | Obes (Lond). 2018;42(9):1602-1609. Proactive identification of clinical features, and appropriate referral for genetic confirmation using correct gene panels can help move children living with a rare MC4R pathway disease onto their most appropriate care path.⁵



Access to appropriate tools means genetic variants that cause rare MC4R pathway diseases can be diagnosed early.⁵

The diagnosis pathway⁵

Patient visits HCP to discuss symptoms

HCP identifies clinical features

HCP refers patient for genetic testing

Through a correct referral, children with genetic variants that cause rare MC4R pathway diseases can be screened, and appropriately cared for

Genetic testing results confirm if the patient has a rare MC4R pathway disease Current genetic screening allows many more rare diseases to be identified – rare MC4R pathway diseases can now be part of this

If you need more information on genetic confirmation or locating expert centres in your country, please visit our website <u>Path4hcps.com</u>, accessible via the QR code:



References:

1. Loos, RJF and Yeo, GSH. Nat Rev Gens. 2022;23:120–133. 2. Heymsfield SB, et al. Obesity (Silver Spring). 2014;22(suppl 1):S1–S17 3. Kohlsdorf K, et al. Int J Obes (Lond). 2018;42(9):1602–1609 4. Hampl SE, et al. Pediatrics. 2023;151(2):e2022060640 5. Styne DM, et al. J Clin Endocrinol Metab. 2017;102(3):709–757

© 2024. Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. INT-DSE-2400084 07/2024